Purpose <p>Evaluate the utility of intraoperative traction (IOT) during posterior spinal fusion (PSF) in a matched cohort at a high-volume neuromuscular scoliosis (NMS) center.</p> Methods <p>A nested case–control study was performed on a single-center retrospective database of NMS patients. Those diagnosed with cerebral palsy were pair-matched by age (± 1&#xa0;year), preoperative curve magnitude (± 10°), preoperative traction curve magnitude (± 10°), and flexibility index (± 5%). Paired <i>t</i> tests or Wilcoxon signed-rank tests were used to analyze continuous variables between groups. Fisher’s Exact tests were used to compare categorical variables by group.</p> Results <p>Thirty-one unique case–control matches were identified (<i>n</i> = 62). IOT and non-IOT groups were similar in terms of EBL 855 (IQR 500–1200) vs. 800 (IQR 650–1350) cc (<i>p</i> = 0.60), length of ICU stay 1.7 (IQR 1.0–2.7) vs. 2.3 (IQR 1.7–3.1) days (<i>p</i> = 0.14), BMI 18.0 (IQR 14–20) vs. 15.5 (IQR 14–18) (<i>p</i> = 0.10), sex distribution 54.8% vs. 51.6% (<i>p</i> &gt; 0.99), and changes in neuromonitoring signals 4/31 (13%) vs. 3/31 (10%) (<i>p</i> &gt; 0.99). Complication rate was 22.6% (7/31) for IOT and 25.8% (8/31) for non-IOT (<i>p</i> &gt; 0.999). There were no statistical differences in surgical time 414 ± 131 vs. 397 ± 133&#xa0;min (<i>p</i> = 0.64) or anesthesia time 551 ± 136 vs. 529 ± 135&#xa0;min (<i>p</i> = 0.56). Both groups had similar postoperative curve magnitude IOT = 37° vs. non-IOT = 42° (<i>p</i> = 0.28) and percent curve correction IOT = 60% vs. non-IOT = 56% (<i>p</i> = 0.30). Percent correction of pelvic obliquity was also similar 78% (IQR 67–90) vs. 68% (IQR 60–91) (<i>p</i> = 0.18) between groups.</p> Conclusion <p>There was no difference in postoperative curve correction or pelvic obliquity between those treated with IOT versus those without during PSF.</p> Level of Evidence <p>III.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Intraoperative traction does not improve curve correction or pelvic obliquity within a matched cohort of patients with neuromuscular scoliosis

  • Ian Fletcher,
  • Alastair W. Sterns,
  • Jacquelyn N. Valenzuela-Moss,
  • Tyler A. Tetreault,
  • Tiffany Phan,
  • Efrain Amaro,
  • Gerard K. Williams,
  • Lindsay M. Andras,
  • Michael J. Heffernan

摘要

Purpose

Evaluate the utility of intraoperative traction (IOT) during posterior spinal fusion (PSF) in a matched cohort at a high-volume neuromuscular scoliosis (NMS) center.

Methods

A nested case–control study was performed on a single-center retrospective database of NMS patients. Those diagnosed with cerebral palsy were pair-matched by age (± 1 year), preoperative curve magnitude (± 10°), preoperative traction curve magnitude (± 10°), and flexibility index (± 5%). Paired t tests or Wilcoxon signed-rank tests were used to analyze continuous variables between groups. Fisher’s Exact tests were used to compare categorical variables by group.

Results

Thirty-one unique case–control matches were identified (n = 62). IOT and non-IOT groups were similar in terms of EBL 855 (IQR 500–1200) vs. 800 (IQR 650–1350) cc (p = 0.60), length of ICU stay 1.7 (IQR 1.0–2.7) vs. 2.3 (IQR 1.7–3.1) days (p = 0.14), BMI 18.0 (IQR 14–20) vs. 15.5 (IQR 14–18) (p = 0.10), sex distribution 54.8% vs. 51.6% (p > 0.99), and changes in neuromonitoring signals 4/31 (13%) vs. 3/31 (10%) (p > 0.99). Complication rate was 22.6% (7/31) for IOT and 25.8% (8/31) for non-IOT (p > 0.999). There were no statistical differences in surgical time 414 ± 131 vs. 397 ± 133 min (p = 0.64) or anesthesia time 551 ± 136 vs. 529 ± 135 min (p = 0.56). Both groups had similar postoperative curve magnitude IOT = 37° vs. non-IOT = 42° (p = 0.28) and percent curve correction IOT = 60% vs. non-IOT = 56% (p = 0.30). Percent correction of pelvic obliquity was also similar 78% (IQR 67–90) vs. 68% (IQR 60–91) (p = 0.18) between groups.

Conclusion

There was no difference in postoperative curve correction or pelvic obliquity between those treated with IOT versus those without during PSF.

Level of Evidence

III.